Overview
Tesamorelin is a synthetic analog of human growth hormone-releasing hormone (GHRH) consisting of the full 44-amino-acid sequence of GHRH with a trans-3-hexenoic acid group conjugated to the N-terminus. This modification significantly enhances metabolic stability compared to native GHRH while preserving full biological activity at the GHRH receptor. Tesamorelin is notable for being the only GHRH analog to receive FDA approval. It is approved under the brand name Egrifta® for the reduction of excess visceral adipose tissue (VAT) in HIV-infected patients with antiretroviral therapy-associated lipodystrophy. This clinical validation provides a robust human pharmacokinetic, pharmacodynamic, and safety dataset that distinguishes tesamorelin from most research peptides. By stimulating GH release and downstream insulin-like growth factor (IGF-1) production, tesamorelin supports improvements in
Mechanism of Action
Tesamorelin acts as a selective agonist at the GHRH receptor (GHRHR) on pituitary somatotroph cells, activating the same adenylyl cyclase → cAMP → PKA signaling cascade as native GHRH. This triggers the synthesis and pulsatile release of endogenous growth hormone, which in turn stimulates hepatic IGF-1 production. The mechanism underlying tesamorelin's specific effect on visceral adipose tissue (VAT) involves GH-mediated stimulation of lipolysis in visceral fat depots. GH activates hormone-sensitive lipase (HSL) in adipocytes, promoting the breakdown of stored triglycerides. Visceral adipocytes are particularly sensitive to GH-mediated lipolysis due to their higher density of GH receptors a
Research Evidence
- FDA-approved (Egrifta®) for HIV-associated lipodystrophy — only approved GHRH analog
- Reduces visceral adipose tissue by ~15–20% in clinical trials (Falutz et al., 2010)
- Increases serum IGF-1 levels, confirming GH axis activation in human subjects
- Preserves pulsatile GH secretion pattern, maintaining physiological GH dynamics
- Potential cognitive benefits investigated in mild cognitive impairment studies (Baker et al., 2021)
Bottom line: Tesamorelin is unique in this catalog because it has FDA approval for a specific indication, meaning it has completed the full clinical trial process. The research-grade lyophilized powder supplied by Purgo Labs is for laboratory use only and differs from the clinical formulation. Its approval status makes it one of the most clinically validated GHRH analogs available for research.
Research Protocols & Dosage
Evidence-based research protocols, administration routes, and dosage considerations for Tesamorelin are detailed in the full compound profile. See also: Dosage guide for Tesamorelin.
Sourcing & Quality
Tesamorelin is available from Purgo Labs with third-party COA verification and research-grade purity standards. View Tesamorelin at Purgo Labs.